NEW YORK, NY / ACCESSWIRE / May 21, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
AnaptysBio, Inc. (NASDAQ:ANAB)
Investors Affected : October 10, 2017 - November 7, 2019
A class action has commenced on behalf of certain shareholders in AnaptysBio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company’s Phase 2a trial in atopic dermatitis, including the timing and extent of patients’ use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company’s Phase 2a trial in peanut allergy, including patients’ average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company’s decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants’ positive statements about the efficacy and prospects of AnaptysBio’s lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/anaptysbio-inc-loss-submission-form/?id=6754&from=1
Gossamer Bio, Inc. (NASDAQ:GOSS)
The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering.
A class action has commenced on behalf of certain shareholders in Gossamer Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer’s GB001 trial failures; (2) the purported clinical validation of Novartis’ oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/gossamer-bio-inc-loss-submission-form/?id=6754&from=1
Zoom Video Communications, Inc. (NASDAQ:ZM)
Investors Affected : April 18, 2019 - April 6, 2020
A class action has commenced on behalf of certain shareholders in Zoom Video Communications, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Zoom had inadequate data privacy and security measures; (ii) contrary to Zoom’s assertions, the Company’s video communications service was not end-to-end encrypted; (iii) as a result of all the foregoing, users of Zoom’s communications services were at an increased risk of having their personal information accessed by unauthorized parties, including Facebook; (iv) usage of the Company’s video communications services was foreseeably likely to decline when the foregoing facts came to light; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/zoom-video-communications-inc-loss-submission-form/?id=6754&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm